Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,024 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the transaction, the chief executive officer now owns 195,686 shares in the company, valued at $25,141,737.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total value of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The stock was sold at an average price of $105.16, for a total transaction of $277,412.08.
• On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36.
• On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The stock was sold at an average price of $108.10, for a total transaction of $4,053,750.00.

Natera Trading Up 0.0 %

Shares of NASDAQ:NTRA opened at $127.13 on Friday. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $132.01. The firm has a fifty day moving average price of $114.12 and a 200 day moving average price of $105.05. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $15.61 billion, a PE ratio of -40.75 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the prior year, the firm posted ($0.97) EPS. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. Analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new stake in shares of Natera during the 2nd quarter worth $28,000. Principal Securities Inc. acquired a new position in Natera during the 4th quarter worth $32,000. Quarry LP boosted its holdings in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new position in shares of Natera in the first quarter worth about $36,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. UBS Group decreased their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. BTIG Research raised their price objective on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Robert W. Baird upped their target price on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Canaccord Genuity Group raised their price target on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, TD Cowen boosted their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $120.07.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.